BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26617391)

  • 1. Microenvironmental hypoxia regulates FLT3 expression and biology in AML.
    Sironi S; Wagner M; Kuett A; Drolle H; Polzer H; Spiekermann K; Rieger C; Fiegl M
    Sci Rep; 2015 Nov; 5():17550. PubMed ID: 26617391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.
    van Oosterwijk JG; Buelow DR; Drenberg CD; Vasilyeva A; Li L; Shi L; Wang YD; Finkelstein D; Shurtleff SA; Janke LJ; Pounds S; Rubnitz JE; Inaba H; Pabla N; Baker SD
    J Clin Invest; 2018 Jan; 128(1):369-380. PubMed ID: 29227282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
    Kojima K; McQueen T; Chen Y; Jacamo R; Konopleva M; Shinojima N; Shpall E; Huang X; Andreeff M
    Blood; 2011 Oct; 118(16):4431-9. PubMed ID: 21868571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
    Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
    Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.
    Kazi JU; Rönnstrand L
    Mol Oncol; 2013 Jun; 7(3):402-18. PubMed ID: 23246379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BEX1 acts as a tumor suppressor in acute myeloid leukemia.
    Lindblad O; Li T; Su X; Sun J; Kabir NN; Levander F; Zhao H; Lu G; Rönnstrand L; Kazi JU
    Oncotarget; 2015 Aug; 6(25):21395-405. PubMed ID: 26046670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
    J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
    Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
    Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
    Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
    Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-155 regulative network in FLT3 mutated acute myeloid leukemia.
    Salemi D; Cammarata G; Agueli C; Augugliaro L; Corrado C; Bica MG; Raimondo S; Marfia A; Randazzo V; Dragotto P; Di Raimondo F; Alessandro R; Fabbiano F; Santoro A
    Leuk Res; 2015 Aug; 39(8):883-96. PubMed ID: 26055960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.].
    Xu B; Shi PC; Song XY; Tang JH; Zhou SY
    Ai Zheng; 2009 Jun; 28(6):632-6. PubMed ID: 19635202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
    Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
    Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia.
    Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DD
    Mol Cancer; 2014 Apr; 13():79. PubMed ID: 24708856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octamer-binding transcription factor 4 correlates with complex karyotype, FLT3-ITD mutation and poorer risk stratification, and predicts unfavourable prognosis in patients with acute myeloid leukaemia.
    Xiang Y; Zhou X
    Hematology; 2018 Dec; 23(10):721-728. PubMed ID: 29950146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.